Independent reviewers
All clinical content is reviewed by a US-licensed MD, PharmD, RD, or JD before publication. Reviewers are paid a flat fee — not commission.
Editorial policy →For journalists
Press & media kit.
Working on a story about GLP-1 pricing, FDA shortages, or telehealth? We can help with editorial commentary, data points from the partner network, and on-record quotes from our editorial board.
Fast facts.
- Founded
- 2026
- Headquarters
- United States
- Coverage
- GLP-1 medications + telehealth partners
- Editorial reviewers
- 4 (MD, PharmD, RD, JD)
- Partner network
- 12+ US telehealth providers
- States served
- All 50 + DC
Topics we can speak to.
- GLP-1 pricing variation (cash-pay vs insurance)
- Compounded vs FDA-approved GLP-1 regulatory landscape
- Telehealth + state-by-state prescribing rules
- Off-label GLP-1 prescribing (diabetes drugs for weight loss)
- Affiliate-model transparency in health media
- FDA shortage resolutions and downstream compounding
Editorial standards.
Source transparency
Every clinical claim cites the FDA prescribing information or a peer-reviewed trial. Pricing is verified monthly with each partner.
Affiliate disclosure
GLP1Zoom earns commission via partner referrals — FTC §255 compliant. Editorial ratings are independent of commission rate.
Full disclosure →Brand assets.
Wordmark, logo, and brand color tokens available on request. We'll send a zip with PNG + SVG assets, color values, and usage guidelines within one business day.